Is Amarin's Luck About to Change?

Amarin  (NASDAQ: AMRN  ) soared over 25% last Friday after announcing that the U.S. Food and Drug Administration, or FDA, has decided to delay its review of the company's supplemental new drug application, or sNDA, for the ANCHOR label expansion for Vascepa. The Prescription Drug User Fee Act, or PDUFA, was scheduled for last Friday, but is being delayed because Amarin has appealed the agency's decision to rescind ANCHOR's Special Protocol Assessment, or SPA. A new PDUFA date will be set after the agency completes its review of the SPA appeal, which should occur by Jan. 15, 2014, according to the press release.

What's Vascepa?
As a reminder, Vascepa is a highly refined fish oil pill currently approved for use in patients with severely high triglycerides. The ANCHOR indication would allow the company to market the pill to patients with moderately high triglycerides -- a much larger target population than its currently approved label.

The FDA reversing itself on the SPA issue could justify the agency going against its Advisory Committee's 2-9 vote against expanding Vascepa's label. However, I am doubtful that this will be the ultimate outcome. The FDA's not known for dramatically reversing course on regulatory matters such as this one. So my view is that ANCHOR's SPA repeal will be upheld, and Vascepa's sNDA will be rejected.

Market outlook
At the end of the day, Amarin is most likely going to have to find a competitive niche for Vascepa in the severely high triglyceride marketplace, at least for the time being. And you don't have to look beyond GlaxoSmithKline's (NYSE: GSK  ) competing fish oil pill Lovaza to see that there is immense commercial potential for this indication.

Namely, Lovaza is also only approved for use as a treatment for severely high triglycerides, yet the pill is expected to top $1 billion in sales this year. As further proof that there is strong demand for these types of drugs, AbbVie's (NYSE: ABBV  ) Tricor-Trilipix combo, indicated for high triglycerides, also generates sales in the hundreds of millions.  And even Tricor's generic formulation, marketed by Mylan, has remarkably high sales figures in this crowded market space.

Foolish final words
In sum, I think Foolish investors should take this appeal's process with a grain of salt. The company initiated the appeal, not the FDA. As such, I view this appeal as little more than the FDA extending professional courtesy to Amarin, and not that the agency realized it made a mistake in repealing ANCHOR's SPA in the first place. For investors with a long-term outlook, I think it's best to focus on Vascepa's commercial potential with its current label and not on the unlikely event that the company's luck with the FDA is about to change for the better.

Growth stock to watch today

Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.


Read/Post Comments (3) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 23, 2013, at 7:49 PM, Zumantu wrote:

    Mr. Budwell, you already look very foolish, the appeal came from here the EPA Drug Initiative Do your homework ! the FDA Citizens Petition filed is to delay PUDFA date AND reinstate SPA and was part of the CP and is found here http://epadruginitiative.com/

  • Report this Comment On December 24, 2013, at 12:09 PM, bohdan wrote:

    Mr. Budwell, I disagree with your assessment. The whole of the circumstances surrounding both the rescinding of the SPA and the negative 9-2 ADCOM vote was a bad surprise, and appeared deeply flawed by many, many observers. In addition, these FDA actions also set a very bad precedent. This latest re-consideration may be an allowance by the FDA for a do-over. The FDA did not have to allow any appeal. Approval of is not locked in by any means, but at least the door was re-opened by the FDA. That is greatly significant in itself. It appears that the FDA recognizes there were errors in process.

  • Report this Comment On December 24, 2013, at 6:47 PM, Bidmark wrote:

    Hey Bud, Bid here. Do us all a favor. If you want to write an article that says the FDA isn't going to change its decision on rescinding the SPA and that they will not approve the Anchor indication, at the very least use some facts (those ugly little things they talk about in journalism school) to support your argument. Why not tell the readers what the FDA's scientific and regulatory reasons are and why they sufficiently negate Amarin's argument? But I suppose it is easier to simply say "I think, therefore I'm right"!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2772301, ~/Articles/ArticleHandler.aspx, 8/30/2014 10:26:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement